CN1331473C - Application of 20(S)-ginsenoside-Rg#[3] in the preparing process of medicine for treating or preventing cardiovascular and cerebrovascular disease - Google Patents
Application of 20(S)-ginsenoside-Rg#[3] in the preparing process of medicine for treating or preventing cardiovascular and cerebrovascular disease Download PDFInfo
- Publication number
- CN1331473C CN1331473C CNB2004100548008A CN200410054800A CN1331473C CN 1331473 C CN1331473 C CN 1331473C CN B2004100548008 A CNB2004100548008 A CN B2004100548008A CN 200410054800 A CN200410054800 A CN 200410054800A CN 1331473 C CN1331473 C CN 1331473C
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- group
- rgs
- medicine
- ginsenoside rgs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title abstract description 15
- 208000026106 cerebrovascular disease Diseases 0.000 title abstract description 10
- 230000002526 effect on cardiovascular system Effects 0.000 title description 10
- 208000024172 Cardiovascular disease Diseases 0.000 title description 9
- 206010019280 Heart failures Diseases 0.000 claims abstract description 17
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 7
- 208000029028 brain injury Diseases 0.000 claims abstract description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 3
- 230000006931 brain damage Effects 0.000 claims abstract description 3
- 231100000874 brain damage Toxicity 0.000 claims abstract description 3
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 claims description 82
- 238000002360 preparation method Methods 0.000 claims description 36
- 230000002265 prevention Effects 0.000 claims description 11
- CKUVNOCSBYYHIS-SUEBGMEDSA-N (2r,3r,4s,5s,6r)-2-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-17-[(2r)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-SUEBGMEDSA-N 0.000 description 21
- 241000700159 Rattus Species 0.000 description 18
- 241000282326 Felis catus Species 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 229940089161 ginsenoside Drugs 0.000 description 8
- 229930182490 saponin Natural products 0.000 description 8
- 150000007949 saponins Chemical class 0.000 description 8
- 235000017709 saponins Nutrition 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 5
- 201000006474 Brain Ischemia Diseases 0.000 description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- 210000000269 carotid artery external Anatomy 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 206010008118 cerebral infarction Diseases 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- 206010048962 Brain oedema Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 208000006752 brain edema Diseases 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000036513 peripheral conductance Effects 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 3
- 206010000117 Abnormal behaviour Diseases 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012982 microporous membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000053227 Themus Species 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 230000005622 photoelectricity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
The invention relates to an application of 20(S)-ginsenoside-Rg[3] in the preparing process of medicine for treating or preventing cerebrovascular disease, brain damage, myocardial ischemia, congestive heart failure.
Description
The art field
The present invention relates to 20 (S)-ginsenoside Rgs
3Application in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease.
Background technology
Along with the acceleration of aged tendency of population process and the change of life style, cardiovascular and cerebrovascular disease has become a global health problem, the mortality rate of coronary heart disease, apoplexy occupies the 1st, 3 respectively at world wide, and hypertension is considered to the main hazard factor of apoplexy always.The exploitation that novel and effective is prevented and treated the cardiovascular and cerebrovascular vessel medicine is very urgent.
20 (S)-ginsenoside Rgs
3It is the tetracyclic triterpenes panoxadiol type saponin monomer of separation and Extraction from Radix Ginseng.
20 (S)-ginsenoside Rgs
3Structural formula (R:-glu-o-glu; R
1:-OH; R
2:-CH
3)
It is reported Rg
3Have antitumor, suppress effects such as new vessels generation, antiinflammatory, but about 20 (S)-ginsenoside Rgs
3Effect with prevention or treatment cardiovascular and cerebrovascular disease does not appear in the newspapers; Given this, the inventor finds 20 (S)-ginsenoside Rgs by a large amount of experimentatioies
3Medical usage with prevention or treatment cardiovascular and cerebrovascular disease.
Summary of the invention
The invention provides 20 (S)-ginsenoside Rgs
3Application in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease.
The invention provides 20 (S)-ginsenoside Rgs
3Application in the medicine of preparation treatment or prevention of brain damage.
The invention provides 20 (S)-ginsenoside Rgs
3Application in the medicine of preparation treatment or prevention myocardial ischemia.
The invention provides 20 (S)-ginsenoside Rgs
3Application in preparation treatment or prevention congestive heart failure medicine.
The invention provides and contain 20 (S)-ginsenoside Rgs
3The pharmaceutical composition of treatment cardiovascular and cerebrovascular disease.
20 (S)-ginsenoside Rgs of the present invention
3When being used for above-mentioned arbitrary purposes, its using dosage scope is 10mg～750mg/ days, preferred 100mg～500mg/ days.
20 (the S)-ginsenoside Rgs that use among the present invention
3Can use separately or use with pharmaceutical compositions.Pharmaceutical composition comprises 20 (S)-ginsenoside Rgs as active component
3And pharmaceutical carrier.This pharmaceutical composition can pass through vein, oral, Sublingual, percutaneous, through muscle or subcutaneous, mucocutaneous administration.Pharmaceutical composition can exist with the form of tablet, pill, granule, capsule, suspension, solution, syrup, injection.Various pharmaceutical dosage form provided by the present invention all can be prepared from the pharmacy conventional method.
The inventor has confirmed 20 (S)-ginsenoside Rgs by following test
3Effect with treatment cardiovascular and cerebrovascular disease.20 (R)-ginsenoside Rgs
3, 20 (S)-ginsenoside Rgs
3Provided by natural drug Engineering Technical Research Centre pharmaceutical chemistry research department, Shandong Province, through HPLC detection level 〉=90%, reference substance is provided by the natural drug Engineering Technical Research Centre chamber of analysis and research, Shandong Province.20 (S) and 20 (R) ginsenoside Rg
3Press document [Zhao Zhongzhen waits the .HPLC method to separate and detects 20 (S)-ginsenoside Rg3s and 20 (R)-ginsenoside Rg3s for Tang Minghui, Jiang Zhihong. Chinese herbal medicine .2003,35 (3): 208～282.] described method detects.20 (R)-ginsenoside Rgs
3Also can be available from Nat'l Pharmaceutical ﹠ Biological Products Control Institute.
The specific embodiment
Preparation example 1:20 (S)-ginsenoside Rg
3With 20 (R)-ginsenoside Rgs
3Preparation
With Radix Notoginseng total arasaponins (or Radix Ginseng total saponins) is raw material, the aqueous acetic acid of adding 50%, 70 ℃ of heating in water bath 6 hours, cooling adds 5% sodium carbonate liquor, solution is through n-butanol extraction, behind the extract evaporate to dryness, last silicagel column is an eluant with the chloroform-methanol, carry out gradient elution, obtain 20 (S)-ginsenoside Rgs
3With 20 (R)-ginsenoside Rgs
3Crude product, through silica gel column chromatography repeatedly, obtain 20 (S)-ginsenoside Rgs respectively
3With 20 (R)-ginsenoside Rgs
3And press document [Zhao Zhongzhen waits the .HPLC method to separate and detects 20 (S)-ginsenoside Rg3s and 20 (R)-ginsenoside Rg3s for Tang Minghui, Jiang Zhihong. Chinese herbal medicine .2003,35 (3): 208～282.] described method detects.
Preparation example 2:20 (S)-ginsenoside Rg
3The injection preparation
Take by weighing 0.50g 20 (S)-ginsenoside Rg
3, add 50g PEG-400, make the saponin dissolving; The phosphate buffer of preparation 50g pH5.5 takes by weighing the 0.02g sodium sulfite and joins in the above-mentioned phosphate buffer; Buffer is joined in the PEG solution of saponin, mix homogeneously adds 100 ℃ of insulations of 0.01% needle-use activated carbon 30 minutes, G
3Sintered glass funnel filters, the filtering with microporous membrane of 0.22um, and filtered liquid medicine is distributed into 50 of the injections that 2ml/ props up, and divides the directly tamponade of injection, the jewelling that install to cover into injection.
Preparation 3: injection 20 (S)-ginsenoside Rg
3The freeze-dried powder preparation
Take by weighing 0.50g 20 (S)-ginsenoside Rg
3, add 50g PEG-400, make the saponin dissolving.The phosphate buffer of preparation 50g pH5.5 takes by weighing the 0.02g sodium sulfite and joins in the above-mentioned phosphate buffer; Buffer is joined in the PEG solution of saponin, mix homogeneously adds 100 ℃ of insulations of 0.01% needle-use activated carbon 30 minutes, G
3Sintered glass funnel filters, the filtering with microporous membrane of 0.22um; Filtered liquid medicine is distributed in the cillin bottle that 2ml/ props up, and makes freeze-dried powder through the freeze dryer lyophilizing.
Preparation example 4: injection 20 (R)-ginsenoside Rg
3The freeze-dried powder preparation
Take by weighing 0.50g20 (R)-ginsenoside Rg
3, add 50g PEG-400, make the saponin dissolving.The phosphate buffer of preparation 50g pH5.5 takes by weighing the 0.02g sodium sulfite and joins in the above-mentioned phosphate buffer; Buffer is joined in the PEG solution of saponin, mix homogeneously adds 100 ℃ of insulations of 0.01% needle-use activated carbon 30 minutes, G
3Sintered glass funnel filters, the filtering with microporous membrane of 0.22um; Filtered liquid medicine is distributed in the cillin bottle that 2ml/ props up, and makes freeze-dried powder through the freeze dryer lyophilizing.
Preparation example 5:20 (S)-ginsenoside Rg
3With 20 (R)-ginsenoside Rgs
3The reference substance preparation
With Radix Notoginseng total arasaponins (or ginsenoside) is raw material, the aqueous acetic acid of adding 50%, 70 ℃ of heating in water bath 6 hours, cooling adds 5% sodium carbonate liquor, solution is through n-butanol extraction, behind the extract evaporate to dryness, last silicagel column is an eluant with the chloroform-methanol, carry out gradient elution, obtain 20 (S)-ginsenoside Rgs
3With 20 (R)-ginsenoside Rgs
3Crude product, through silica gel column chromatography repeatedly, obtain 20 (S)-ginsenoside Rgs respectively
3With 20 (R)-ginsenoside Rgs
3Elaboration, recrystallization repeatedly obtains reference substance then.
Test routine 1:20 (S)-ginsenoside Rg
3Influence to the damage of rat local cerebral ischemia
(1) material
By preparation example 2 preparations 20 (S)-ginsenoside Rgs
3
By preparation example 4 preparations 20 (R)-ginsenoside Rgs
3
Red tetrazolium: U.S. Sigma company product, face with preceding and be made into 4% solution with normal saline.
Laboratory animal: the SD rat, male, body weight 280g-350g, natural drug Engineering Technical Research Centre zoopery center, Shandong Province provides.The quality certification number: No. 200106005, Shandong kinoplaszm word.
(2) method and result
Animal is divided into sham operated rats (waiting the capacity solvent) at random, model control group (waiting the capacity solvent), the nimodipine group (Nim, 1.5mg/kg), 20 (R)-ginsenoside Rgs
3The 5mg/kg group, 20 (S)-ginsenoside Rgs
3The 1mg/kg group, 20 (S)-ginsenoside Rgs
3The 5mg/kg group, 20 (S)-ginsenoside Rgs
3The 10mg/kg group, 20 (S)-ginsenoside Rgs
3The 20mg/kg group, 20 (S)-ginsenoside Rgs
3The 50mg/kg group, 20 (S)-ginsenoside Rgs
3The 75mg/kg group, 10 every group.After the fasting 12 hours, and chloral hydrate (350mg/kg, i.p.) anesthesia separates right carotid, and folder closes in the neck, common carotid artery, external carotid artery proximal part and distal end ligation, cut off the centre.The external carotid artery free-end is pulled to internal carotid artery in alignment, bolt line (selecting diameter 0.24mm nylon wire for use, length 5.0cm) is inserted into intracranial by external carotid artery, stop when meeting slight resistance, insertion depth is about 2cm.Ligation external carotid artery opening, and open the common carotid artery bulldog clamp, the disinfection and stitching wound causes right side middle cerebral artery ischemia model; Sham operated rats is only carried out the separation (above experiment is all carried out at 23 ℃～25 ℃) of right carotid, internal carotid artery, external carotid artery.Each treated animal intravenous injection relative medicine of postoperative (administration volume 1ml/200g).Press document [Liu Xiaoguang, Xu Lina, a kind of rat brain medium-sized artery model that can estimate thrombolytic and anti-thrombolytic after 24 hours, Acta Pharmaceutica Sinica, 1995,30:662] described method and standard is observed and the behavior disorder of record rat: (A) carry the Mus tail and observe forelimb flexing situation, stretch to ground as two forelimb symmetries, count 0 fen, the wrist flexing occurs as operation offside forelimb and count 1 fen, the elbow flexing is counted 2 fens, the shoulder inward turning is counted 3 fens, existing wrist flexing and/or elbow flexing have shoulder inward turning person again, count 4 fens.(B) animal is placed on the plane earth, push away both shoulders respectively, check resistance to side shifting.As bilateral resistance equity and strong, count 0 fen, as resistance descender when the operation offside promotes, according to decline degree difference be divided into gently, in, weigh three degree, count 1,2 and 3 fen respectively.(C) the two forelimbs of animal are put on the wire netting, observed the muscular tension of two forelimbs.Two muscle of anterior limb tension force equities and strong person count 0 fen.Count l, 2 and 3 minutes according to operation offside muscular tension decline degree difference equally.(D) animal has ceaselessly to a side person of turn-taking, and counts 1 fen.According to the standard scoring, full marks are 11 minutes, and mark is high more, and expression animal behavior obstacle is serious more.
Put to death rat behind the behavior scoring, get brain, remove olfactory bulb, cerebellum and low brain stem, crownly be cut into 5, the brain sheet takes on a red color after normal structure is dyed with red tetrazolium (TTC) dyeing, and blocking tissue is white in color, taking a picture in dyeing back, asks the infarct size ratio with Chinese Aero-Space university pathological image analysis software.Data are used
± s represents, carries out statistical procedures with t check between group.
The result is shown in table l, and ischemia is after 24 hours, and rat shows tangible behavior disorder, and tangible kitchen range shape ischemic region also appears in rat cerebral tissue, reaches about 25% of full brain; Give 20 (S)-ginsenoside Rgs of various dose
3, the animal behavior obstacle has alleviating in various degree, and the rat cerebral ischemia district also takes an evident turn for the better, and is dose dependent.
20 (S)-ginsenoside Rgs of same dose
3Treating cerebral ischemia is better than 20 (R)-ginsenoside Rgs
3: 20 (S)-ginsenoside Rgs
3The 50mg/kg treating cerebral ischemia is better than 20mg/kg (P＜0.05), but does not relatively have significant difference (P＞0.05) with 75mg/kg.Prompting is when dosage 〉=50mg/kg, and drug effect does not continue increase.
Table 1 20 (S)-ginsenoside Rg
3Influence to the damage of rat local cerebral ischemia
| Group | Behavior disorder | Ischemic areas (%) |
| Sham operated rats model control group Nim organizes 20 (R)-ginsenoside Rgs 3Group (10mg/kg) 1mg/kg 5mg/kg 20 (S)-ginsenoside 10mg/kg Rg 3Group 20mg/kg 50mg/kg 75mg/kg | 0 10.10±1.37 6.90±2.33 **8.03±1.11 *7.90±1.24 *7.70±2.44 *7.50±3.03 *@7.31±1.08 **Δ5.34±1.28 **5.20±1.93 **# | 0 24.26±4.13 13.09±7.11 ** 20.24±1.3 * 18.21±2.73 * 17.06±3.20 * 16.41±2.84 *@ 14.22±3.14 **Δ 10.18±3.64 **10.27 the scholar 4.73 **# |
Compare with model control group
*P＜0.05,
*P＜0.01; Compare with the 50mg/kg group
ΔP＜0.05,
#P＞0.05; With 10mg/kg20 (R)-ginsenoside Rg
3Group relatively
@P＜0.05.
Test routine 2:20 (S)-ginsenoside Rg
3Protective effect to mice closure cerebral trauma
(1) material: by preparation example 2 preparations 20 (S)-ginsenoside Rgs
3, by preparation example 4 preparations 20 (R)-ginsenoside Rgs
3Cleaning level kunming mouse, 18～22g, male and female half and half are provided by natural drug Engineering Technical Research Centre zoopery center, Shandong Province.The quality certification number: No. 200106003, Shandong kinoplaszm word.
(2) method and result: mice is divided into normal control group (waiting the capacity solvent) at random, model control group (waiting the capacity solvent), 20 (R)-ginsenoside Rgs
3The 20mg/kg group, 20 (S)-ginsenoside Rgs
3The 2mg/kg group, 20 (S)-ginsenoside Rgs
3The 10mg/kg group, 20 (S)-ginsenoside Rgs
3The 20mg/kg group, 20 (S)-ginsenoside Rgs
3The 40mg/kg group, 20 (S)-ginsenoside Rgs
3The 100mg/kg group, 20 (S)-ginsenoside Rgs
3The 150mg/kg group, 10 every group.Press document [Wang Chaoyun, Jiang Wanglin, the red English of intelligence, etc. baicalin is to the protective effect of brain injury. Chinese herbal medicine, 2004,35 (2): 188～190] described method causes mice closure cerebral trauma model, and each organizes intravenously administrable, strips the Mus brain after 24 hours, the weighing weight in wet base, dried 24 hours for 70 ℃, claim dry weight, calculate brain water content; Brain water content is higher than normal value and represents the brain edema.
The result is as shown in table 2, and the closure cerebral trauma causes the serious edema of mouse brain, gives 20 (S)-ginsenoside Rgs of various dose
3, the mouse brain edema has alleviating in various degree, and is dose dependent.
20 (S)-ginsenoside Rgs of same dose
3Reduce the cerebral edema effect and be better than 20 (R)-ginsenoside Rgs
320 (S)-ginsenoside Rgs
3100mg/kg reduces the cerebral edema effect and is better than 40mg/kg (P＜0.05), but does not relatively have significant difference (P＞0.05) with 150mg/kg.Prompting is when dosage 〉=100mg/kg, and drug effect does not continue increase.
Table 2 20 (S)-ginsenoside Rg
3Influence to the closure cerebral trauma
| Group | Brain water content (%) |
| Normal control group model matched group 20 (R)-ginsenoside Rgs 3Group (10mg/kg) 2mg/kg 10mg/kg 20mg/kg 20 (S)-ginsenoside Rgs 3Group 40mg/kg 100mg/kg 150mg/kg | 76.1±0.3 ** 84.5±1.3 81.1±1.1 * 81.6±0.4 * 79.9±0.3 * 79.8±0.5 *@ 79.7±0.4 **Δ 77.4±0.4 ** 76.5±0.3 **# |
Compare with model control group
*P＜0.05,
*P＜0.01; Compare with the 100mg/kg group
ΔP＜0.05,
#P＞0.05; With 20mg/kg 20 (R)-ginsenoside Rg
3Group relatively
@P＜0.05.
Test routine 3:20 (S)-ginsenoside Rg
3Influence to the rat heart muscle ischemia
(1) material: by preparation example 3 preparations 20 (S)-ginsenoside Rgs
3
Chlorination nitro blue tetrazolium (N-BT) is provided by Military Medical Science Institute medical supply station.
Laboratory animal: regular grade Wistar rat, male, body weight 280g-350g, natural drug Engineering Technical Research Centre zoopery center, Shandong Province provides.The quality certification number: No. 200106005, Shandong kinoplaszm word.
(2) method and result: rat is divided into sham operated rats at random, model control group (waiting the capacity solvent), 20 (S)-ginsenoside Rgs
3The 1mg/kg group, 20 (S)-ginsenoside Rgs
3The 5mg/kg group, 20 (S)-ginsenoside Rgs
3The 10mg/kg group, 20 (S)-ginsenoside Rgs
3The 20mg/kg group, 20 (S)-ginsenoside Rgs
3The 50mg/kg group, 20 (S)-ginsenoside Rgs
3The 75mg/kg group, 10 every group.After the fasting 12 hours, the limb lead electrocardiogram is surveyed in ip urethane (1.2g/kg) anesthesia.Cut off left front fur, iodine tincture and alcohol disinfecting, along left border of sternum 1cm place, cut off thoracic wall muscle and two ribs, open the thoracic cavity rapidly, expose heart, the ligation left coronary artery is put back to heart immediately between arterial cone and left auricle, squeezes the thoracic cavity air, use the mosquito forceps closed-chest, cause Model Rats with Acute Myocardial Ischemia.Each treated animal intravenous drip (injecting) relative medicine (administration volume 3ml, 30min drips off) of postoperative with infusion pump.Record postoperative 0,2, the 6h electrocardiogram takes out heart subsequently, after cleaning with cold saline ,-20 ℃ of refrigerator freeze overnight.Next day, refrigerated heart is cut into 5 by ligation place to apex uniform thickness, immerse in the freshly prepared 0.5%N-BT phosphate buffer (pH7.4).37 ℃ of water-bath jolting 10～15min.Blot the dyeing liquor of slice surface with filter paper, separate the coloured portions and the part of being unstained, weigh the compute infarct size.Myocardial infarction percentage ratio (%)=infarction part weight/(non-infarction part weight+infarction part weight) * 100%.
The result is as shown in table 3,20 (S)-ginsenoside Rgs of various dose
3Obviously reduce the myocardial infarction area that Acute Myocardial Ischemia in Rats causes due to the ligation coronary artery, and can reduce the rising of the limb lead electrocardiogram J point that causes by myocardial ischemia.20 (S)-ginsenoside Rgs
3The 50mg/kg function of resisting myocardial ischemia is better than 20mg/kg (P＜0.05), but relatively do not have significant difference (P＞0.05) with 75mg/kg, and promptly when dosage 〉=50mg/kg, drug effect does not continue increase.
Table 3 20 (S)-ginsenoside Rg
3Influence to the rat heart muscle ischemic injuries
| Grouping | Myocardial infarction percentage ratio (%) | The J point raises (10 * mV) | |||
| Normally | 0h | 2h | 6h | ||
| Model control group danshen injections group 1mg/kg 5mg/kg 20 (S)-ginsenoside 10mg/kg Rg3 20mg/kg 50mg/kg 75mg/kg | 24±4 17±6 * 19±7 * 18±5 * 18±5 * 17±6 *Δ 14±5 ** 13±6 **# | 0.8±0.6 0.8±0.6 0.7±0.5 0.7±0.6 0.7±0.5 0.7±0.5 0.7±0.6 0.7±0.5 | 6.7±2.3 6.0±1.5 * 6.1±1.2 * 5.9±1.5 * 5.6±1.6 * 5.3±1.1 *Δ 4.6±1.6 * 4.4±1.3 *# | 6.3±2.0 5.6±1.7 * 5.6±1.6 * 5.3±1.2 * 4.9±1.6 * 4.8±1.3 *Δ 4.2±1.4 * 4.1±1.6 *# | 5.9±1.5 * 5.6±1.6 * 4.9±1.2 * 4.8±1.6 * 4.2±1.1 * 4.1±1.5 *Δ 3.5±1.0 * 3.4±1.1 *# |
Compare with model control group
*P＜0.05,
*P＜0.01; Compare with the 50mg/kg group
ΔP＜0.05,
#P＞0.05.
Test routine 4:20 (s)-ginsenoside Rg
3Therapeutical effect to the experimental heart failure of cat
(1) material: 20 (S)-ginsenoside Rgs
3Injection: by preparation example 3 preparations.
The Powerlab/8sp physiograph: Australian InStruments company produces.
Electromagnetic flowmeter (MFV-3200 type): Japanese photoelectricity company produces.
Laboratory animal: healthy adult cat body weight 2～4kg, natural drug Engineering Technical Research Centre zoopery center, Shandong Province provides.
(2) method: cat is divided into model control group (waiting the capacity solvent), 20 (S)-ginsenoside Rgs at random
3Small dose group (5mg/kg), 20 (S)-ginsenoside Rgs
3Middle dosage group (10mg/kg), 20 (S)-ginsenoside Rgs
3Heavy dose of group (20mg/kg), 6 every group.After the fasting 12 hours, intravenous injection pentobarbital sodium 40mg/kg anesthesia, tracheal intubation, artificial respiration, monitoring aortic pressure (AP) and electrocardiogram.Breast is opened in the left side, plugs in conduit to left ventricle from the apex of the heart, surveys left constant pressure and rate of pressure change (± dP/dt thereof
Max).Waltan-Brodie strain bow is implanted the left ventricle antetheca, measure myocardial contraction.With electromagnetic flowmeter determination ascending aorta blood flow.As cardiac output (CO), calculate cardiac index (CI), the index (SI) of whenever fighting, the work done (SW) of whenever fighting, left heart work done (LVW) and total peripheral vascular resistance (SVR) with the ascending aorta flow.Parameters is recorded in the Powerlab/8sp physiograph.Postoperative half an hour, it is stable that parameters reaches.From femoral vein constant speed gasing injection pentobarbital sodium (0.5ml/kgmin), with ± dP/dt
MaxDropping to about 1000mmHg/s is that leading indicator forms acute heart failure.After treating the heart failure model stability, each treated animal intravenous drip (injecting) relative medicine (administration volume 1Oml, 30min drips off) with infusion pump.
(3) result:
A, 20 (S)-ginsenoside Rg
3Influence to heart failure cat heart rate and blood pressure
The result is as shown in table 4, instillation various dose 20 (S)-ginsenoside Rg
3Can reduce heart failure cat blood pressure in various degree, and particularly evident to the effect of diastolic pressure.
Table 420 (S)-ginsenoside Rg
3Influence to heart failure cat blood pressure
| Grouping | Mean arterial pressure (mmHg) | Systolic pressure (mmHg) | Diastolic pressure (mmHg) | |||
| Before the administration | After the administration | Before the administration | After the administration | Before the administration | After the administration | |
| Model control group 20 (S)-ginsenoside 20mg/kg Rg 3 10mg/kg 5mg/kg | 57±5 55±4 59±6 62±5 | 53±6 38±8 **## 43±9 *# 45±7 * | 71±11 73±14 70±9 73±10 | 69±10 64±8 *# 66±7 67±8 | 45±8 47±6 41±7 42±6 | 44±8 27±5 **## 30±6 **## 35±3 *# |
With comparison before the administration
*P＜0.05,
*P＜0.01; Compare with model control group
#P＜0.05,
##P＜0.01
B, 20 (S)-ginsenoside Rg
3Influence to heart failure cat cardiac work
The result is as shown in table 5, instillation various dose 20 (S)-ginsenoside Rg
3Can increase SW and the LVW of heart failure cat, with before the administration, model control group relatively has significant difference.
Table 520 (S)-ginsenoside Rg
3Influence to heart failure cat cardiac work
| Grouping | Whenever the work done (gm/beat) of fighting | Left side heart work done (kgm/min) | ||
| Before the administration | After the administration | Before the administration | After the administration | |
| Model control group 20 (S)-Radix Ginseng soap 20mg/kg glycosides Rg 3 10mg/kg 5mg/kg | 0.98±0.33 0.86±0.41 0.89±0.32 0.93±0.38 | 0.87±0.56 1.23±0.51 **## 1.08±O.47 *# 1.01±0.50 # | 0.064±0.033 0.066±0.036 0.059±0.032 0.061±0.031 | 0.059±0.032 0.087±0.041 **## 0.079±0.036 *# 0.070±0.029 # |
With comparison before the administration
*P＜0.05,
*P＜0.01; Compare with model control group
*P＜0.05,
*P＜0.01
C, 20 (S)-ginsenoside Rg
3Influence to the total peripheral vascular resistance of heart failure cat
The result is as shown in table 6, instillation various dose 20 (S)-ginsenoside Rg
3Can reduce the total outer vascular resistance of heart failure cat, with before the administration, model control group relatively has significant difference.
Table 620 (S)-ginsenoside Rg
3Influence to the total peripheral vascular resistance of heart failure cat
| Grouping | Total peripheral vascular resistance (mmHg/min/kg) | |
| Before the administration | After the administration | |
| Model control group 20 (S)-ginsenoside Rg 3 20mg/kg 10mg/kg 5mg/kg | 79±27 81±30 83±28 82±30 | 82±33 51±22 **##64±30 **##71±33 *# |
With comparison before the administration
*P＜0.05,
*P＜0.01; Compare with model control group
#P＜0.05,
##P＜0.01
D, 20 (S)-ginsenoside Rg
3To the kinemic influence of heart failure cat
The result is as shown in table 7, instillation various dose 20 (S)-ginsenoside Rg
3Can increase the cardiac output of heart failure cat, with before the administration, model control group relatively has significant difference.
Table 720 (S)-ginsenoside Rg
3To the kinemic influence of heart failure cat
| Grouping | Stroke volume index (ml/beatm 2) | Cardiac output index (L/minm 2) | ||
| Before the administration | After the administration | Before the administration | After the administration | |
| Model control group 20mg/kg 20 (S)-Radix Ginseng soap 10mg/kg glycosides Rg 3 5mg/kg | 4.5±0.9 4.4±1.2 5.1±1.6 4.8±0.9 | 4.1±1.2 8.1±3.5 **##7.2±3.3 **##5.9±1.1 *# | 0.65±0.15 0.67±0.20 0.66±0.17 0.67±0.21 | 0.59±0.18 0.88±0.23 **##0.79±0.16 *#0.73±0.19 # |
With comparison before the administration
*P＜0.05,
*P＜0.01; Compare with model control group
#P＜0.05,
##P＜0.01
Test routine 5:20 (S)-ginsenoside Rg
3Acute toxicity test
(1) material: 20 (S)-ginsenoside Rgs
3Injection: by preparation example 2 preparations.
Cleaning level kunming mouse, 18～22g, male and female half and half are provided by natural drug Engineering Technical Research Centre zoopery center, Shandong Province.The quality certification number: No. 200106003, Shandong kinoplaszm word.Feedstuff identifies that by Chinese pharmaceutical biological product check is provided.
(2) method: according to trial test design dosage and the blank group of dividing into groups, 100mg/kg, 150mg/kg, 225mg/kg, 337.5mg/kg, 506.25mg/kg, 759.375mg/kg group, totally 8 groups, 10 every group.After weighing, press the volume intravenous injection of 0.2ml/10g, matched group gives the equal-volume solvent.Toxic reaction of close observation mice and death condition in 7 days after the administration, and measure LD by improving karber's method
50
(3) result
20 (S)-ginsenoside Rgs
3The LD of injection
50Be 408.7 ± 78.6mg/kg; LD
5095% fiducial limit: 349.2～529.5mg/kg.
Claims (3)
1.20 (S)-ginsenoside Rg
3Application in the medicine of preparation treatment or prevention of brain damage.
2.20 (S)-ginsenoside Rg
3Application in the medicine of preparation treatment or prevention myocardial ischemia.
3.20 (S)-ginsenoside Rg
3Application in the medicine of preparation treatment or prevention congestive heart failure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100548008A CN1331473C (en) | 2003-07-23 | 2004-07-22 | Application of 20(S)-ginsenoside-Rg#[3] in the preparing process of medicine for treating or preventing cardiovascular and cerebrovascular disease |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03132942 | 2003-07-23 | ||
| CN03132942.X | 2003-07-23 | ||
| CNB2004100548008A CN1331473C (en) | 2003-07-23 | 2004-07-22 | Application of 20(S)-ginsenoside-Rg#[3] in the preparing process of medicine for treating or preventing cardiovascular and cerebrovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1593442A CN1593442A (en) | 2005-03-16 |
| CN1331473C true CN1331473C (en) | 2007-08-15 |
Family
ID=34679644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100548008A Expired - Fee Related CN1331473C (en) | 2003-07-23 | 2004-07-22 | Application of 20(S)-ginsenoside-Rg#[3] in the preparing process of medicine for treating or preventing cardiovascular and cerebrovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1331473C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1905444B1 (en) * | 2005-07-14 | 2014-09-24 | Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd | Preparation method of a medicinal composition containing ginseng secondary glycosides |
| CN105168233A (en) * | 2015-09-23 | 2015-12-23 | 浙江大学 | Application of 20(S)-ginsenoside Rg3 as SIRT1 protein agonist |
-
2004
- 2004-07-22 CN CNB2004100548008A patent/CN1331473C/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 人参皂苷rg3对肺癌诱导血管内皮细胞增殖的抑制作用 王兵等，中国新药杂志，第11卷第9期 2002 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1593442A (en) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100544744C (en) | Method, its application in antiinflammatory and analgesic of extraction and purification active component from stem of Caulis Lonicerae | |
| CN101311160B (en) | Method for preparing red sage root salviandic acid A | |
| CN1689575B (en) | Application of ocotillol in the preparing process of medicine for treating or preventing cardiovascular and cerebrovascular disease | |
| CN101230003B (en) | Preparation method of salvia miltiorrhiza tanshinoate A | |
| CN101596182A (en) | Contain pharmaceutical composition, its preparation method, the purposes of salviol acid A and contain the lyophilized injectable powder and the aqueous injection of said composition | |
| CN101342274B (en) | Curculigo orchioides extract, preparation method and uses thereof | |
| CN107412430A (en) | A kind of radix scrophulariae water extract and its application | |
| CN101759672B (en) | Salvianolic acid B in radix salviae miltiorrhizae | |
| CN1331473C (en) | Application of 20(S)-ginsenoside-Rg#[3] in the preparing process of medicine for treating or preventing cardiovascular and cerebrovascular disease | |
| CN102274260A (en) | Medicinal composition of notoginseng root extract and preparation method thereof | |
| Koo et al. | Extraction of hypotensive principles from seeds of Cassia tora | |
| CN1698717B (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
| CN103505612A (en) | Traditional Chinese medicine composition containing total flavonoids of sea-buckthorn and preparation method of composition | |
| CN100512829C (en) | Silktree albizzia general saponin and its extraction method, pharmaceutical use of the said composition and medicine preparation | |
| CN101152246B (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN101696166B (en) | Preparation method for danshen root salvianolic acid A | |
| CN101744938B (en) | Pharmaceutical composition and preparation method thereof | |
| CN101176772B (en) | Pharmaceutical composition made of cattail pollen and safflower | |
| CN1326520C (en) | A pharmaceutical composition and application thereof in preparation of medicine for preventing or treating cerebrovascular and cardiovascular disease | |
| CN104825505B (en) | The Actinidia valvata leaf composition to resist myocardial ischemia | |
| CN103505488A (en) | Traditional Chinese medicine composition of pseudo-ginseng and sea-buckthorn and preparation method of composition | |
| CN1911219B (en) | Medicine composition, and its application | |
| CN101161268B (en) | Pharmaceutical composition of red sage root and cattail pollen | |
| CN106491672A (en) | Otoginsenoside composition of sodium and preparation method thereof | |
| CN101190253B (en) | Medicinal composition containing mongolian snakegourd and notoginseng |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Succession or assignment of patent right |
Owner name: DAZHENG INTERNATIONAL ECONOMY AND TRADE, CHANGCHU Free format text: FORMER OWNER: LUYE NATURAL MEDICINAL RESEARCH DEVELOPING CO., LTD., SHANDONG PROV. Effective date: 20050128 |
|
| C06 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20050128 Address after: Changchun City, Jilin Province Long Road 5 km long Kazakhstan (102 National Road) Applicant after: Changchun grand international economic and trade (Group) Pharmaceutical Co., Ltd. Address before: No. 9, Po Yuen Road, Laishan District, Yantai, Shandong Applicant before: Luye Natural Medicinal Research Developing Co., Ltd., Shandong Prov. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20060331 Address after: 264003, No. 9, Po Yuen Road, Laishan District, Shandong, Yantai Applicant after: Luye Natural Medicinal Research Developing Co., Ltd., Shandong Prov. Address before: Changchun City, Jilin Province Long Road 5 km long Kazakhstan (102 National Road) Applicant before: Changchun grand international economic and trade (Group) Pharmaceutical Co., Ltd. |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170608 Address after: 264670, No. 15, pioneering Road, hi tech Zone, Shandong, Yantai Patentee after: Shandong Luye Pharma Co., Ltd. Address before: 264003 Laishan, Shandong Province Bao Road, No. 9 District, No. Patentee before: Luye Natural Medicinal Research Developing Co., Ltd., Shandong Prov. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180208 Address after: No. 458, Zhifu District, Zhifu District, Shandong Province, Shanghai Patentee after: Shandong Tong Yu Tang ginseng Technology Co., Ltd. Address before: 264670, No. 15, pioneering Road, hi tech Zone, Shandong, Yantai Patentee before: Shandong Luye Pharma Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070815 Termination date: 20180722 |